Journal
JOURNAL OF MEDICAL PRIMATOLOGY
Volume 51, Issue 5, Pages 278-283Publisher
WILEY
DOI: 10.1111/jmp.12613
Keywords
HIV cure strategies; HIV; HIV reservoir; immunotherapy; immune checkpoint blocker; latency reversal
Categories
Funding
- National Health and Medical Research Council
- National Institutes of Health
- Delaney AIDS Research Enterprise [UM1 AI164560-01]
Ask authors/readers for more resources
Although multiple latency reversal agents have shown activity in vitro, clinical trials have not demonstrated significant reduction in latently infected cells. New insights into the biology of HIV latency are being reviewed and novel approaches to enhance the efficacy of latency reversal agents are being discussed.
One strategy to eliminate latently infected cells that persist in people with HIV on antiretroviral therapy is to activate virus transcription and virus production to induce virus or immune-mediated cell death. This is called latency reversal. Despite clear activity of multiple latency reversal agents in vitro, clinical trials of latency-reversing agents have not shown significant reduction in latently infected cells. We review new insights into the biology of HIV latency and discuss novel approaches to enhance the efficacy of latency reversal agents.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available